ITI-1001
/ HLB Bio Group
- LARVOL DELTA
Home
Next
Prev
1 to 11
Of
11
Go to page
1
March 26, 2024
Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
(clinicaltrials.gov)
- P1 | N=10 | Active, not recruiting | Sponsor: Immunomic Therapeutics, Inc. | Trial primary completion date: Jun 2025 ➔ Mar 2026 | Recruiting ➔ Active, not recruiting
Enrollment closed • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • CD163 • CD8 • FOXP3
January 01, 2024
Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
(clinicaltrials.gov)
- P1 | N=10 | Recruiting | Sponsor: Immunomic Therapeutics, Inc.
Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • CD163 • CD8 • FOXP3
August 24, 2023
Immunomic Therapeutics Doses First Patient in its Phase 1 Clinical Trial of ITI-1001, a pDNA Vaccine for the Treatment of Glioblastoma Multiforme
(Businesswire)
- "Immunomic Therapeutics, Inc...today announced dosing of the first patient in its Phase 1 clinical trial evaluating ITI-1001, a plasmid DNA (pDNA) vaccine, for the treatment of Glioblastoma Multiforme (GBM), a rare but aggressive form of brain cancer. The study is being conducted at the Dana-Farber Cancer Institute in Boston, Massachusetts and is being led by Dr. David Reardon, Clinical Director, Center for Neuro-Oncology....The single-center, open label, First-In-Human Phase 1 clinical trial is designed to evaluate the safety, tolerability, immunogenicity and preliminary efficacy of 8 mg of ITI-1001 in newly diagnosed GBM patients having unmethylated MGMT promoter mutations."
Trial status • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
August 14, 2023
Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
(clinicaltrials.gov)
- P1 | N=10 | Recruiting | Sponsor: Immunomic Therapeutics, Inc. | Not yet recruiting ➔ Recruiting | Initiation date: Apr 2023 ➔ Aug 2023 | Trial primary completion date: Dec 2024 ➔ Jun 2025
Enrollment open • Trial initiation date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
March 01, 2023
Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
(clinicaltrials.gov)
- P1 | N=10 | Not yet recruiting | Sponsor: Immunomic Therapeutics, Inc. | Initiation date: Jan 2023 ➔ Apr 2023
Trial initiation date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
January 31, 2023
HLB subsidiary Immunomic begins full-scale clinical trial of 'ITI-1001' in the US [Google Translation]
(PRESS9)
- "Immunomic Therapeutics...a subsidiary of HLB, started clinical trials in earnest about eight months after applying for an IND (clinical trial protocol) to the U.S. Food and Drug Administration (FDA) for a glioblastoma treatment vaccine. According to Clinical Trials, a clinical information site of the National Institutes of Health (NIH) on the 31st, Immunonomic tested the safety, tolerability, immunogenicity and preliminary efficacy of the DNA vaccine 'ITI-1001' in 10 patients with glioblastoma. started a phase 1 clinical trial in the US this month to evaluate....The primary indicators are dose-limiting toxicity (DLT) serious adverse events/number of serious adverse events. The clinical trial period is until December 2023."
Trial status • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
January 26, 2023
Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
(clinicaltrials.gov)
- P1 | N=10 | Not yet recruiting | Sponsor: Immunomic Therapeutics, Inc.
New P1 trial • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
June 04, 2022
Development and Characterization of an HCMV Multi-Antigen Therapeutic Vaccine for Glioblastoma Using the UNITE Platform.
(PubMed, Front Oncol)
- "Further characterization of these two groups showed high infiltration of CD3+, CD4+, and CD8+ T cells in responders compared to non-responders. Thus, we show that vaccination with HCMV antigens using the ITI-1001-UNITE platform generates strong cellular and humoral immune responses, triggering significant antitumor activity, leading to enhanced survival in a mouse model of GBM."
Journal • Brain Cancer • Cytomegalovirus Infection • Glioblastoma • Oncology • Solid Tumor • CD4 • CD8 • IFNG • LAMP1
April 29, 2021
[VIRTUAL] Development and characterization of a HCMV multiantigen therapeutic vaccine for GBM using the UNITE platform.
(ASCO 2021)
- "Thus, we show that vaccination with HCMV antigens using the ITI-1001-UNITE platform generates strong cellular and humoral immune responses, triggering significant anti-tumor activity that leads to enhanced survival in mice with GBM."
Brain Cancer • Cytomegalovirus Infection • Glioblastoma • Oncology • Solid Tumor • CD4 • CD8 • IFNG • LAMP1
June 16, 2020
Immunomic Therapeutics enters into license agreement with Ichor Medical Systems to use electroporation (EP) delivery technology in phase I study of DNA vaccine therapy, ITI-1001
(PRNewswire)
- "Immunomic Therapeutics, Inc...and Ichor Medical Systems...announced today that the companies have entered into a license agreement to support the development of ITI’s investigational plasmid DNA vaccine therapy, ITI-1001...In the planned First-In-Human Phase I trial, ITI will evaluate the safety, tolerability, immunogenicity and preliminary efficacy of ITI-1001 in patients with newly-diagnosed GBM having unmethylated MGMT promoter mutations. The Phase I trial is anticipated to start in 2021."
Licensing / partnership • New P1 trial • Glioblastoma • Oncology
March 03, 2020
Immunomic Therapeutics announces completion of pre-IND meeting with US FDA for ITI-1001, a vaccine for the treatment of GBM
(Businesswire)
- "Immunomic Therapeutics, Inc...announced today that it successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding its First-In-Human (FIH) Phase I trial and development plans for ITI-1001. The FDA addressed the Company’s questions and provided feedback on key components of the planned IND application for the candidate, ITI-1001, for the treatment of newly diagnosed Glioblastoma Multiforme (GBM)....The Phase 1 trial is anticipated to start in 2021."
FDA event • New P1 trial
1 to 11
Of
11
Go to page
1